Back to Journals » Therapeutics and Clinical Risk Management » Volume 1 » Issue 2

Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence

Authors David RP Guay

Published 15 July 2005 Volume 2005:1(2) Pages 157—166

David RP Guay

Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA

Abstract: Trospium chloride is a quaternary ammonium compound, which is a competitive antagonist at muscarinic cholinergic receptors. Preclinical studies using porcine and human detrusor muscle strips demonstrated that trospium chloride was many-fold more potent than oxybutynin and tolterodine in inhibiting contractile responses to carbachol and electrical stimulation. The drug is poorly bioavailable orally (< 10%) and food reduces absorption by 70%– 80%. It is predominantly eliminated renally as unchanged compound. Trospium chloride, dosed 20 mg twice daily, is significantly superior to placebo in improving cystometric parameters, reducing urinary frequency, reducing incontinence episodes, and increasing urine volume per micturition. In active-controlled trials, trospium chloride was at least equivalent to immediate-release formulations of oxybutynin and tolterodine in efficacy and tolerability. The most problematic adverse effects of trospium chloride are the anticholinergic effects of dry mouth and constipation. Comparative efficacy/tolerability data with long-acting formulations of oxybutynin and tolterodine as well as other anticholinergics such as solifenacin and darifenacin are not available. On the basis of available data, trospium chloride does not appear to be a substantial advance upon existing anticholinergics in the management of urge urinary incontinence.

Keywords: urge incontinence, trospium, anticholinergic, overactive bladder

Download Article [PDF] 

Readers of this article also read:

Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents

Estelrich J, Sánchez-Martín MJ, Busquets MA

International Journal of Nanomedicine 2015, 10:1727-1741

Published Date: 6 March 2015

Lifestyle changes as a treatment of gastroesophageal reflux disease: a survey of general practitioners in North Queensland, Australia

Madeleine Nowak, Petra Büttner, Beverly Raasch, Kym Daniell, Cindy McCutchan, Simone Harrison

Therapeutics and Clinical Risk Management 2005, 1:219-224

Published Date: 15 October 2005

Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy

Charity D Scripture, William D Figg, Alex Sparreboom

Therapeutics and Clinical Risk Management 2005, 1:107-114

Published Date: 15 July 2005

Renal replacement therapy in the intensive care unit

Neesh Pannu, RT Noel Gibney

Therapeutics and Clinical Risk Management 2005, 1:141-150

Published Date: 15 July 2005